THE COMBINED GENOMIC AND IMMUNOHISTOCHEMICAL TUMOR PROFILING AS
A TOOL OF PRECISION ONCOLOGY APPROACH IN THE REAL-WORLD COHORT
OF PATIENTS WITH GYNECOLOGICAL CANCERS

a 2023

THE COMBINED GENOMIC AND IMMUNOHISTOCHEMICAL TUMOR PROFILING AS A TOOL OF PRECISION ONCOLOGY APPROACH IN THE REAL-WORLD COHORT OF PATIENTS WITH GYNECOLOGICAL CANCERS

BEDNAŘÍKOVÁ, Markéta, Michal EID, Lucie EHRLICHOVÁ, Jitka HAUSNEROVÁ, Sára VILMANOVÁ et. al.

Základní údaje

Originální název

THE COMBINED GENOMIC AND IMMUNOHISTOCHEMICAL TUMOR PROFILING AS A TOOL OF PRECISION ONCOLOGY APPROACH IN THE REAL-WORLD COHORT OF PATIENTS WITH GYNECOLOGICAL CANCERS

Autoři

Vydání

ESGO 2023 Congress, 2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.800 v roce 2022

Organizační jednotka

Lékařská fakulta

ISSN

DOI

http://dx.doi.org/10.1136/ijgc-2023-ESGO.458

Změněno: 14. 11. 2023 12:26, Mgr. Tereza Miškechová

Anotace

V originále

Introduction/Background The program of the applied precision oncology approach using combined genomic and immunohistochemical (IHC) analyses to develop individual treatment plans in adult patients (pts) with solid tumors has been established in University Hospital Brno since March 2021. We hereby report the results achieved in patients with gynecological tumors. Methodology Patients undergoing systemic treatment with palliative intent are referred to Molecular Tumor Board (MTB). Whenever possible, the molecular analyses using next-gene sequencing (NGS) together with IHC analyses of key potential targets as requested by the referring physician are performed. The patients whose tumors show an aberration are treated with matched targeted therapy proposed by MTB, when available. Results Between March 2021 and April 2023, 76 pts with gynecological tumors were referred to MTB; 45 (59%) with ovarian cancer, 15 (20%) uterine cancer, 11 (14%) cervical cancer, 4 (5%) with vaginal/vulvar cancer and 1 (1%) with both ovarian and uterine cancer. Median age at the time of profiling was 59 years, median time from the tumor sampling to profiling was 17 months. Results of profiling were available for 68 tumors with actionable aberrations detected in 49 samples (72%). Based on NGS, actionable genomic signature was found in 13/68 tumors (19%) and gene alterations with targeted therapy available in 30/68 tumors (44%). In total, only 2 samples (3%) did not meet the quality criteria for NGS. By IHC, PDL1 positivity (≥1 either by TPS or CPS) was detected in 32/58 examined tumors (57%), MMR-deficiency in 5/56 tumors (9%) and HER-2 positivity in 2/19 tumors (11%). So far, proposed matched therapy has been started in 16/49 patients (33%) with median time of duration 74.5 days compared to 63.5 days within the prior line of treatment. Conclusion Combined genomic and immunohistochemical profiling of gynecological tumors is an efficient approach to match patients with targeted therapy.

Návaznosti

NU21-03-00306, projekt VaV

Název: Komplexní genomové profilování u pacientek s karcinomem ovaria léčených platinovými deriváty: identifikace prediktivních biomarkerů a ověření využitelnosti precizní onkologie

Investor: Ministerstvo zdravotnictví ČR, Komplexní genomové profilování u pacientek s karcinomem ovaria léčených platinovými deriváty: identifikace prediktivních biomarkerů a ověření využitelnosti precizní onkologie, Podprogram 1 - standardní

Citovat

BEDNAŘÍKOVÁ, Markéta, Michal EID, Lucie EHRLICHOVÁ, Jitka HAUSNEROVÁ, Sára VILMANOVÁ, Alena KOPKOVÁ, Renata TASLEROVÁ, Martina JELÍNKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Petra OVESNÁ, Martin GRYC, Ondřej SLABÝ a Vít WEINBERGER. THE COMBINED GENOMIC AND IMMUNOHISTOCHEMICAL TUMOR PROFILING AS A TOOL OF PRECISION ONCOLOGY APPROACH IN THE REAL-WORLD COHORT OF PATIENTS WITH GYNECOLOGICAL CANCERS. In ESGO 2023 Congress. 2023. ISSN 1048-891X. Dostupné z: https://dx.doi.org/10.1136/ijgc-2023-ESGO.458.

@proceedings{2339182,
   author = {Bednaříková, Markéta and Eid, Michal and Ehrlichová, Lucie and Hausnerová, Jitka and Vilmanová, Sára and Kopková, Alena and Taslerová, Renata and Jelínková, Martina and Minář, Luboš and Felsinger, Michal and Ovesná, Petra and Gryc, Martin and Slabý, Ondřej and Weinberger, Vít},
   booktitle = {ESGO 2023 Congress},
   doi = {http://dx.doi.org/10.1136/ijgc-2023-ESGO.458},
   language = {eng},
   title = {THE COMBINED GENOMIC AND IMMUNOHISTOCHEMICAL TUMOR PROFILING AS A TOOL OF PRECISION ONCOLOGY APPROACH IN THE REAL-WORLD COHORT OF PATIENTS WITH GYNECOLOGICAL CANCERS},
   url = {https://ijgc.bmj.com/content/33/Suppl_3/A220.3},
   year = {2023}
}

TY  - CONF
ID  - 2339182
AU  - Bednaříková, Markéta - Eid, Michal - Ehrlichová, Lucie - Hausnerová, Jitka - Vilmanová, Sára - Kopková, Alena - Taslerová, Renata - Jelínková, Martina - Minář, Luboš - Felsinger, Michal - Ovesná, Petra - Gryc, Martin - Slabý, Ondřej - Weinberger, Vít
PY  - 2023
TI  - THE COMBINED GENOMIC AND IMMUNOHISTOCHEMICAL TUMOR PROFILING AS A TOOL OF PRECISION ONCOLOGY APPROACH IN THE REAL-WORLD COHORT OF PATIENTS WITH GYNECOLOGICAL CANCERS
UR  - https://ijgc.bmj.com/content/33/Suppl_3/A220.3
N2  - Introduction/Background The program of the applied precision oncology approach using combined genomic and immunohistochemical (IHC) analyses to develop individual treatment plans in adult patients (pts) with solid tumors has been established in University Hospital Brno since March 2021. We hereby report the results achieved in patients with gynecological tumors. Methodology Patients undergoing systemic treatment with palliative intent are referred to Molecular Tumor Board (MTB). Whenever possible, the molecular analyses using next-gene sequencing (NGS) together with IHC analyses of key potential targets as requested by the referring physician are performed. The patients whose tumors show an aberration are treated with matched targeted therapy proposed by MTB, when available. Results Between March 2021 and April 2023, 76 pts with gynecological tumors were referred to MTB; 45 (59%) with ovarian cancer, 15 (20%) uterine cancer, 11 (14%) cervical cancer, 4 (5%) with vaginal/vulvar cancer and 1 (1%) with both ovarian and uterine cancer. Median age at the time of profiling was 59 years, median time from the tumor sampling to profiling was 17 months. Results of profiling were available for 68 tumors with actionable aberrations detected in 49 samples (72%). Based on NGS, actionable genomic signature was found in 13/68 tumors (19%) and gene alterations with targeted therapy available in 30/68 tumors (44%). In total, only 2 samples (3%) did not meet the quality criteria for NGS. By IHC, PDL1 positivity (≥1 either by TPS or CPS) was detected in 32/58 examined tumors (57%), MMR-deficiency in 5/56 tumors (9%) and HER-2 positivity in 2/19 tumors (11%). So far, proposed matched therapy has been started in 16/49 patients (33%) with median time of duration 74.5 days compared to 63.5 days within the prior line of treatment. Conclusion Combined genomic and immunohistochemical profiling of gynecological tumors is an efficient approach to match patients with targeted therapy.
ER  -

BEDNAŘÍKOVÁ, Markéta, Michal EID, Lucie EHRLICHOVÁ, Jitka HAUSNEROVÁ, Sára VILMANOVÁ, Alena KOPKOVÁ, Renata TASLEROVÁ, Martina JELÍNKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Petra OVESNÁ, Martin GRYC, Ondřej SLABÝ a Vít WEINBERGER. THE COMBINED GENOMIC AND IMMUNOHISTOCHEMICAL TUMOR PROFILING AS A TOOL OF PRECISION ONCOLOGY APPROACH IN THE REAL-WORLD COHORT OF PATIENTS WITH GYNECOLOGICAL CANCERS. In \textit{ESGO 2023 Congress}. 2023. ISSN~1048-891X. Dostupné z: https://dx.doi.org/10.1136/ijgc-2023-ESGO.458.

Podrobný výpis o publikaci